Adverse Event reporting information can be found in footer

Request a Meeting


(desmopressin [as acetate] oral lyophilisate)

DesmoMelt is a sublingual oral lyophilisate formulation of desmopressin which quickly dissolves when taken1,2. It is licensed for the treatment of primary nocturnal enuresis (PNE) in children and adults aged 5 to 651.

A statistically significant preference for DesmoMelt compared with tablets has been seen in children aged 5-11 years2

DesmoMelt is well accepted by children of various ages and facilitates early intervention2, providing an effective and convenient solution to primary nocturnal enuresis and helping children and families return to a normal life.

Statistically significant superior antidiuretic effect at 3-8 hours after dosing when compared with tablet3

Due to the superior pharmacodynamic characteristics of the melt formulation, more than 25% of patients had a higher diuresis rate with the tablet vs. melt formulation, which was significantly different from hours 3 to 8 after dosing3.


The value of compliance2 with no significant cost burden to NHS4

DesmoMelt is associated with a numerically higher compliance rate than the tablet (94.5% vs. 88.9%; P=0.059, not significant) and retains similar levels of efficacy and safety at lower dosing levels2.

In a study comparing children’s response rates after 2 months’ treatment, overall response rates were better with DesmoMelt5


A single dose (120mcg) of DesmoMelt should be taken before bedtime for a period of 3 months, followed by a 1 week drug-free period to assess results. If symptoms persist, the treatment cycle should be repeated1.

If needed, the dose taken can be increased to 240mcg1.


DesmoMelt is intended for treatment periods of up to 3 months. The need for continued treatment should be reassessed by means of a period of at least 1 week without DesmoMelt1.

For more information about the benefits of DesmoMelt,

Download leaflet

  1. 1. DesmoMelt Summary of Product Characteristics. Available at: Date accessed: March 2023.
  2. 2. Lottman H et al. Int J Clin Pract 2007;61(9):1454–60
  3. 3. De Guchtenaere A et al. J Urol 2011;185(6):2308–13.
  4. 4. NICE costing statement 2010. Nocturnal Enuresis.
  5. 5. Debruyne et al. Poster presented at IC/ERIC/BAJU Joint Congress in London UK, 12-14 October 2012

Job Code: UK-MN-2200029 - Date of preparation: March 2023


Our use of cookies

We use cookies (including third party cookies) to collect data while you use this website in order to make it work, keep it secure and comply with regulations. We’d also like your consent to use cookies so we can provide you with tailored content and advertising and analyse how you and other people use the website.

Select “On” to consent to our use of these cookies and continue to the website, or select “Off” to control which types of cookies we use. You can read more about cookies in our Privacy Policy.

Necessary cookies

Necessary cookies enable core functionality such as security, network management, and accessibility. You may disable these by changing your browser settings, but this may affect how the website functions.

Analytics cookies

We’d like to set Google Analytics cookies to help us to improve our website by collecting and reporting information on how you use it. The cookies collect information in away that does not directly identify anyone. For more information on how these cookies work, please see our Privacy Policy.